Further research into HERV-K(HML-2) as a possible tumour-associated antigen in blood cancers requires a more targeted, proteome-based, screening protocol that will consider these polymorphisms within HERV-K(HML-2). The gene discussed is CLEC10A; the disease is hematopoietic and lymphoid system neoplasm.